Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13383440 | 0.91 | — | — | |
| SCHEMBL13383447 | 0.81 | — | — | |
| SCHEMBL5421979 | 0.78 | — | — | |
| SCHEMBL29427025 | 0.76 | — | — | |
| SCHEMBL5428762 | 0.75 | HTR2A (0.30) | — | |
| SCHEMBL11066162 | 0.75 | — | — | |
| SCHEMBL11076177 | 0.75 | — | — | |
| SCHEMBL14165283 | 0.75 | — | — | |
| SCHEMBL1397182 | 0.72 | — | — | |
| SCHEMBL11771912 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | disclosed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | disclosed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| EP-1866294-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007098962-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| EP-1829862-A1 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006103057-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | SIGMAR1, OPRL1, OPRK1 | OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.